Oral methylphenidate effects on GAP43 and PSD95 expression in the developing brains of Wistar Kyoto rats
DOI:
https://doi.org/10.48797/sl.2024.195Keywords:
PosterAbstract
Background: Attention Deficit Hyperactivity Disorder (ADHD) is a prevalent neuropsychiatric disorder in childhood and adolescence [1]. Differences in brain structure, function, and connectivity were seen between ADHD and healthy individuals [2,3] but the underlying cellular and neurobiological mechanisms of ADHD are not fully understood [3,4]. Objective: To evaluate how clinically relevant oral doses of methylphenidate (MPH), a first-line ADHD treatment, affect body growth and the expression of brain proteins involved in synaptic plasticity, integrity, and neuronal growth. Methods: Wistar-Kyoto rats (18 males and 19 females) were randomly assigned to two groups. The treated group received a daily dose of MPH (5mg/kg in a 5% sucrose solution) by gavage, while the control group received an equivalent volume of 5% sucrose solution [5]. Administration began on postnatal day 15 (equivalent to childhood in humans) and lasted for 15 days, with the doses adjusted individually based on the animal’s weight (25g per 100 microL of drug or vehicle). The animal’s weight was monitored throughout the experiment. On postnatal day 30, the animals were sacrificed, the brain was dissected in separate relevant areas. Liver, heart, and kidneys were also collected. Subsequently, the brain areas were processed by Western Blotting. Results: No statistically significant changes in body and peripheral organ weight were noticed among the control and treated groups in either males or female rats. Furthermore, MPH did not affect the expression of GAP43 and PSD95 proteins in the diencephalon and prefrontal cortex. Moreover, no notable sex differences were observed for these same parameters. Conclusions: Although MPH induced no significant changes in the analyzed parameters in males, females and even no sex related changes, further investigation into new brain areas, markers, and mainly ADHD models is crucial to understand the role of MPH on development.References
1. Banaschewski, T.; Becker K.; Döpfner, M.; Holtmann, M.; Rösler, M.; Romanos M. Attention-Deficit/Hyperactivity Disorder. Dtsch Arztebl Int. (2017) 114(9),149-59.
2. da Silva B.S.; Grevet, E.H.; Silva, L.C.F.; Ramos, J.K.N.; Rovaris, D.L.; Bau, C.H.D. An overview on neurobiology and therapeutics of attention-deficit/hyperactivity disorder. Discover Mental Health (2023) 3(1):2.
3. Posner, J.; Polanczyk, G.V.; Sonuga-Barke, E. Attention-deficit hyperactivity disorder. Lancet (2020) 395(10222):450-62.
4. Faraone, S.V.; Asherson, P.; Banaschewski, T.; Biederman, J.; Buitelaar, J.K.; Ramos-Quiroga, J.A.; et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers (2015) 1:15020.
5. Loureiro-Vieira, S.; Costa, V.M.; Duarte, J.A.; Duarte-Araújo, M.; Gonçalves-Monteiro, S.; Maria de Lourdes, B.; et al. Methylphenidate clinically oral doses improved brain and heart glutathione redox status and evoked renal and cardiac tissue injury in rats. Biomed Pharmacother (2018) 100:551-63.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Patrícia Soares-Couto, Vera Marisa Costa, Ana Dias-Carvalho, Susana Isabel Sá, Mariana Ferreira, Félix Carvalho, João Paulo Capela
This work is licensed under a Creative Commons Attribution 4.0 International License.
In Scientific Letters, articles are published under a CC-BY license (Creative Commons Attribution 4.0 International License), the most open license available. The users can share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as they give appropriate credit, provide a link to the license, and indicate if changes were made (read the full text of the license terms and conditions of use).
The author is the owner of the copyright.
